A Phase 1/2 interventional study of mesenchymal stem cell and saline in AIDS, sponsored by Cell Energy Life Sciences Group Co. LTD. Recruiting at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Cell Energy Life Sciences Group Co. LTD · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Acquired Immunodeficiency Syndrome with a site in China — 22 open to participants now, 24 under way, none of them phase 3. Acquired Immunodeficiency Syndrome · China.
Among the 87 studies in Acquired Immunodeficiency Syndrome with a site in China, this one is the 29th largest by planned enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2023, is one of 9 in phase 1/2, reaches primary completion later than 17 of the 23 other live ones, and was the 66th registered.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →22 of the 87 studies in Acquired Immunodeficiency Syndrome with a site in China are open now. Recruiting first, the newest first:
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 40+
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 16 · Phase 3 7 · Phase 4 4
First in 2005; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 108 across the 68 interventional studies, 400 across the 18 observational. Of the 33 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 87 have an industry lead sponsor. The 10 most frequent:
Cell Energy Life Sciences Group Co. LTD is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Cell Energy Life Sciences Group Co. LTD has 1 study filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Acquired Immunodeficiency Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07519538Southwest Medical UniversitySouthern Sichuan HIV Cohort Study Protocol | 2027-04-30 |
| NCT07577986First Affiliated Hospital of Zhejiang UniversityA Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir | 2027-05-01 |
| NCT07711210Jiangsu Aidea Pharmaceutical Group Co., Ltd.Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations | 2027-06-30 |
| NCT05939167Cell Energy Life Sciences Group Co. LTDMesenchymal Stem Cells Treatment for AIDS Patients at Late Stage | 2027-07-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 87 studies in Acquired Immunodeficiency Syndrome with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
Mesenchymal stem cells (MSCs) possess immunomodulatory, anti-inflammatory, and regenerative properties. The safety and effectiveness of MSCs have been investigated in various clinical trials for the treatment of several disorders, including graft-versushost disease, inflammatory bowel disease, and multiple sclerosis. It has been reported that MSC treatment in HIV-infected patients with immunological nonresponders resulted in a significant increase in circulating CD4+ T lymphocytes and a decrease of the activation of T lymphocytes and soluble inflammation mediator levels without significant adverse effects or loss of viremia control. However, the therapeutic efficacy of MSC treatment for AIDS patients at late stage is not well-understood. This study aims to investigate the safety and efficacy of MSC treatment for AIDS patients at late stage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4. agree not to participate in other studies and not to receive other immunotherapies during the period of participation in this study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
use saline
Other: saline
transplant mesenchymal stem cells for 3 times
Drug: mesenchymal stem cell
transplant mesenchymal stem cells for 6 times
Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).
Also known as: umbilical cord derived MSCs
saline is used as placebo in the placebo comparator group
Number of participants with side effects in MSCs treatment groups
Investiagte the number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after MSCs infusion.
Time frame: 48 weeks
CD4+ T cell counts after MSCs transfusion
at week 12, 24 and 48, evaluate CD4+ T cell counts and compare with baseline
Time frame: 48 weeks
HIV RNA viral load
At week 12, 24 and 48, test HIV RNA viral load in participants' blood using RT-PCR and compare with baseline.
Time frame: 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Jul 2027, 43 months after the start.
Of 29 phase 1/2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 24. This study's planned 43 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mesenchymal Stem Cell
Acquired Immunodeficiency Syndrome →
Cell Energy Life Sciences Group Co. LTD